News

ACH2 grants a terrific outcome

Burnet Institute

13 December, 2019

ACH2 grant recipient, Co-Head Viral Entry and Vaccines Group, Professor Heidi Drummer

Burnet Institute studies ranging from innovative antiviral strategies, to the development of new diagnostics, and research focused on vaccine development have attracted valuable funding from the Australian Centre for HIV and Hepatitis Virology Research (ACH2).

“A terrific outcome” was how Burnet Head of Life Sciences, Professor Gilda Tachedjian described the grants awarded to Professor Heidi Drummer, Associate Professor David Anderson, Dr Rob Center, Dr Jess Howell, Dr Andy Poumbourios, Dr Bruce Wines and Dr Jack Richards. Professor Tachedjian also received a grant.

“Congratulations to our Life Science Discipline researchers and their co-CIs for winning ACH2 funding for translational research in HIV and hepatitis virology,” Professor Tachedjian said.

“The focus of the successful research grants is centred on vaccines, prevention and immunotherapy; diagnostics and prognostics; and antiviral strategies.

“It shows the excellence of our work and the translational nature of our work in taking fundamental research and going that next step to develop a vaccine, diagnostic or antiviral microbicide.

“We’re thrilled to have support from ACH2 to be able to do this important work.”

The funded work focuses on:

Find out more about Burnet research into HIV and viral hepatitis, and translational research.

Contact Details

For more information in relation to this news article, please contact:

Professor Gilda Tachedjian

Head of Life Sciences; Head of Tachedjian Laboratory (Retroviral Biology and Antivirals)

Telephone

+61392822256

Email

gilda.tachedjian@burnet.edu.au

Subscribe to News

Subscribe to receive our latest news: